Gary Nachman
Stock Analyst at Raymond James
(3.70)
# 785
Out of 5,138 analysts
97
Total ratings
58.9%
Success rate
6.01%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Reiterates: Strong Buy | $85 → $89 | $77.68 | +14.57% | 4 | Oct 30, 2025 | |
| BLCO Bausch + Lomb | Reiterates: Outperform | $18 → $19 | $17.35 | +9.51% | 2 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Outperform | $40 → $50 | $18.30 | +173.22% | 3 | Oct 20, 2025 | |
| ABBV AbbVie | Reiterates: Outperform | $236 → $250 | $217.07 | +15.17% | 17 | Oct 17, 2025 | |
| AMGN Amgen | Assumes: Market Perform | n/a | $330.05 | - | 2 | Sep 3, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $2.40 | +735.07% | 2 | Aug 13, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $17.68 | +58.37% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $363.83 | -18.09% | 7 | Nov 1, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $5.60 | +257.14% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $21.09 | +75.44% | 13 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $30 | $46.17 | -35.02% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $3.46 | +102.60% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $170.25 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $13.08 | -69.42% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $14.86 | +101.88% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $4.19 | +663.72% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $12.85 | +8.95% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $32.67 | -69.39% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $38.25 | -21.57% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $4.44 | +16,810.94% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $7.34 | +8.99% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $27.23 | -22.88% | 5 | May 11, 2020 |
Ionis Pharmaceuticals
Oct 30, 2025
Reiterates: Strong Buy
Price Target: $85 → $89
Current: $77.68
Upside: +14.57%
Bausch + Lomb
Oct 30, 2025
Reiterates: Outperform
Price Target: $18 → $19
Current: $17.35
Upside: +9.51%
LENZ Therapeutics
Oct 20, 2025
Reiterates: Outperform
Price Target: $40 → $50
Current: $18.30
Upside: +173.22%
AbbVie
Oct 17, 2025
Reiterates: Outperform
Price Target: $236 → $250
Current: $217.07
Upside: +15.17%
Amgen
Sep 3, 2025
Assumes: Market Perform
Price Target: n/a
Current: $330.05
Upside: -
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $2.40
Upside: +735.07%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $17.68
Upside: +58.37%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $363.83
Upside: -18.09%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $5.60
Upside: +257.14%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $21.09
Upside: +75.44%
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $46.17
Upside: -35.02%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $3.46
Upside: +102.60%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $170.25
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $13.08
Upside: -69.42%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $14.86
Upside: +101.88%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $4.19
Upside: +663.72%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $12.85
Upside: +8.95%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $32.67
Upside: -69.39%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $38.25
Upside: -21.57%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $4.44
Upside: +16,810.94%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $7.34
Upside: +8.99%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $27.23
Upside: -22.88%